Insulin Substrate Receptor (IRS) proteins in normal and malignant hematopoiesis (2018)
- Authors:
- USP affiliated authors: MACHADO NETO, JOÃO AGOSTINHO - ICB ; TRAINA, FABÍOLA - FMRP ; FENERICH, BRUNA ALVES - FMRP ; ALVES, ANA PAULA NUNES RODRIGUES - FMRP ; FERNANDES, JAQUELINE CRISTINA - FMRP ; RIBEIRO, RENATA SCOPIM - FMRP ; SILVA, JUAN LUIZ COELHO DA - FMRP
- Unidades: ICB; FMRP
- DOI: 10.6061/clinics/2018/e566s
- Subjects: RECEPTORES DE INSULINA; LEUCEMIA; HEMATOPOESE; NEOPLASIAS
- Keywords: Insulin Receptor Substrate; Adaptor Protein; Signal Transduction; Hematopoiesis; Leukemia; Myeloproliferative Neoplasms
- Agências de fomento:
- Language: Inglês
- Imprenta:
- Source:
- Status:
- Artigo publicado em periódico de acesso aberto (Gold Open Access)
- Versão do Documento:
- Versão publicada (Published version)
- Acessar versão aberta:
-
ABNT
MACHADO NETO, João Agostinho et al. Insulin Substrate Receptor (IRS) proteins in normal and malignant hematopoiesis. Clinics, v. 73, n. Suppl 1, 2018Tradução . . Disponível em: https://doi.org/10.6061/clinics/2018/e566s. Acesso em: 08 abr. 2026. -
APA
Machado Neto, J. A., Fenerich, B. A., Alves, A. P. N. R., Fernandes, J. C., Scopim-Ribeiro, R., Coelho-Silva, J. L., & Traina, F. (2018). Insulin Substrate Receptor (IRS) proteins in normal and malignant hematopoiesis. Clinics, 73( Suppl 1). doi:10.6061/clinics/2018/e566s -
NLM
Machado Neto JA, Fenerich BA, Alves APNR, Fernandes JC, Scopim-Ribeiro R, Coelho-Silva JL, Traina F. Insulin Substrate Receptor (IRS) proteins in normal and malignant hematopoiesis [Internet]. Clinics. 2018 ; 73( Suppl 1):[citado 2026 abr. 08 ] Available from: https://doi.org/10.6061/clinics/2018/e566s -
Vancouver
Machado Neto JA, Fenerich BA, Alves APNR, Fernandes JC, Scopim-Ribeiro R, Coelho-Silva JL, Traina F. Insulin Substrate Receptor (IRS) proteins in normal and malignant hematopoiesis [Internet]. Clinics. 2018 ; 73( Suppl 1):[citado 2026 abr. 08 ] Available from: https://doi.org/10.6061/clinics/2018/e566s - NT157 has antineoplastic effects and inhibits IRS1/2 and STAT3/5 in JAK2V617F-positive myeloproliferative neoplasm cells
- IGF1R/IRS1 targeting has cytotoxic activity and inhibits PI3K/AKT/mTOR and MAPK signaling in acute lymphoblastic leukemia cells
- Irs1S57X heterozygous mutant mice display normal hematopoiesis and phenotypic features, while homozygous knockout exhibit high fetal or postnatal lethality
- Differential cytotoxic activity of pharmacological inhibitors of IGF1R-related pathways in JAK2V617F driven cells
- NT157, an IGF1R-IRS1/2 inhibitor, exhibits antineoplastic effects in pre-clinical models of chronic myeloid leukemia
- Autophagy inhibition potentiates ruxolitinib-induced apoptosis in JAK2V617F cells
- Differential cytotoxic activity of pharmacological inhibitors of IGF1R-related pathways in JAK2(V617F) driven cells
- De novo AML exhibits greater microenvironment dysregulation compared to AML with myelodysplasia-related changes
- Stathmin 1 expression in plasma cell neoplasms. [Carta]
- Increased levels of cyclin D1 negatively impacts on acute lymphoblastic leukemia overall survival
Informações sobre a disponibilidade de versões do artigo em acesso aberto coletadas automaticamente via oaDOI API (Unpaywall).
Por se tratar de integração com serviço externo, podem existir diferentes versões do trabalho (como preprints ou postprints), que podem diferir da versão publicada.
Download do texto completo
| Tipo | Nome | Link | |
|---|---|---|---|
 |
002959474.pdf | Direct link |
How to cite
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
